NewGenIvf Group Limited (NIVF) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] NewGenIvf Group Ltd (NIVF) 3-Minute Overview > **💡 One-Sentence Summary** > > NewGenIvf is a tiny Thailand-based company listed on Nasdaq that started in fertility/healthcare but is now trying to build a strange mix of fertility tech, digital assets, and real estate projects—more like a speculative “story stock” than a pure medical business. > **📍 Basic Profile** > > Market Cap **$0.98 million** · Health Care (fertility / diversified) · Nasdaq · Price **$1.00** --- > **⚡ 3 Things You Should Know** > > 1. ⚠️ **Micro-cap, almost nano-cap**: A sub-$1m market cap on Nasdaq is extremely small—this trades more like a thinly traded penny stock than a normal healthcare company, so liquidity and volatility risk are huge. > > 2. 🎭 **Weird financials + business mix**: On paper the P/E is absurdly low (~0.06x) and ROE is sky-high (90%+), but that’s almost certainly coming from one-off accounting items or a tiny equity base, not a stable cash machine—plus they’re mixing fertility, digital assets, and Gulf real estate JVs, which is very unconventional and raises “story vs. substance” questions. > > 3. 📰 **Big promises in Ras Al Khaimah project**: Management is talking about converting a UAE joint venture into a joint development that could *almost double* projected profits (from US$67m to US$123m), but given how tiny the company is today, that kind of projection is highly speculative and execution + financing risk is enormous. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |------------------|------------------------|---------| > | Profitability | Medium✋ | Net margin ~12%, but operating margin is deeply negative and metrics look distorted. | > | Growth Rate | [Data unavailable] | No historical revenue/profit trend data provided. | > | Financial Health | Healthy💚 | Very low debt (D/E ~0.00), current ratio >3 suggests no near-term liquidity crunch. | > | Valuation | Looks “ultra-cheap” but unreliable | P/E ~0.06x is likely not a meaningful indicator for a micro-cap with unusual accounting. | --- ## 📋 Layer 2: 2-Minute Deep Dive ### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Runs fertility/IVF-related services and is trying to build a broader ecosystem that now includes digital assets and real estate development partnerships, likely earning from service fees, project stakes, and possibly asset-related income. We don’t have a clean revenue breakdown by segment, but we can infer: **Revenue Breakdown (indicative, not provided):** | Business | Share | Trend | Comment | |-------------------------------------|-------|-------|---------| | Fertility / IVF services | [N/A] | [N/A] | Core “Health Care” anchor, likely original business. | | Digital asset–related initiatives | [N/A] | [N/A] | Very unusual for a fertility firm; likely early-stage, high risk. | | Real estate JVs (e.g., RAK project) | [N/A] | ↑ | Latest news suggests this is a growing focus and key part of the “big plans” story. | **Profitability Metrics (TTM):** | Metric | Value | Ranking | Interpretation | |-----------------|-----------|--------------------|----------------| | Gross Margin | 31.5% | Around industry-average | Reasonable for services, suggests some pricing power. | | Net Margin | 12.4% | Decent for a small firm | On its face, not bad—but must be viewed with caution due to other red flags. | | Operating Margin| -86.2% | Very weak | Implies large operating expenses or one-off charges; something doesn’t add up. | | ROE | 92.6% | Extremely high | For a micro-cap, this often means a tiny equity base or one-off revaluation gains, not sustainable returns. | In other words: the numbers don’t fully “fit together.” A deeply negative operating margin plus a positive net margin and massive ROE suggests unusual items or accounting noise. --- ### 📈 How's the Growth? **Growth Assessment:** [Data unavailable → treat as unknown, not “high growth”] We don’t have explicit year-over-year revenue or profit growth numbers in the data. | Metric | Latest | vs Last Year | Trend | |----------------|--------|--------------|-------| | Revenue Growth | [N/A] | [N/A] | [N/A] | | Profit Growth | [N/A] | [N/A] | [N/A] | **Growth Quality (qualitative):** - The company is **promoting a big step-up in projected profits** from its Ras Al Khaimah (RAK) real estate joint development (talking US$67m → US$123m). - Those are **projected**, not actual results, and come from a venture outside the classic IVF core. - Given the current **market cap is under US$1m**, those numbers are massive relative to today’s size, which makes this look more like a *high-risk “moonshot” narrative* than a quietly compounding healthcare operator. So: any “growth story” here is almost entirely **forward-looking and speculative** rather than backed by a long, stable operating history we can see in the data. --- ### 💰 Financial Health Check **One Sentence:** Balance-sheet-wise, it looks like someone with almost no debt and a decent cash cushion, but earnings are unstable and cash-flow quality is unclear. | Metric | Value | Safe Zone | Assessment | |---------------------|--------|----------------|-----------------| | Debt-to-Equity | 0.0027 | <0.6 | ✅Safe – essentially no leverage. | | Long-term Debt/Equity | 0 | Lower is better| ✅No long-term debt reported. | | Current Ratio (Q) | 3.43 | >1.5 | ✅Comfortable short-term liquidity. | | Quick Ratio (Annual)| 1.06 | >1.0 | ⚠️Just above water; not a big buffer. | | Interest Coverage | -0.244 | >2.0 | ⚠️Negative suggests operating income is weak/negative. | | Cash Flow | [N/A] | >0 | [Data unavailable] | Translation: - **Good:** Very low leverage and a solid current ratio mean they’re **not obviously drowning in debt**. - **Worrying:** Negative interest coverage and that huge negative operating margin flag **weak underlying profitability**, at least in the recent period. - For a company this tiny, **a single failed project or capital raise could be painful.** --- ### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: **$0.385** - 52-Week High: **$930** ← this is almost certainly a data or post-split anomaly; treat with caution. - Current: **$1.00** If we take the raw numbers literally: - Position = (1.00 – 0.385) / (930 – 0.385) ≈ ~0.066% of the 52-week range → **mathematically “near the low”**, but the 930 figure is likely not a meaningful reference. | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|-----------|-----------|-------------| | Criteria | 0–33% | 33–66% | 66–100% | | **Current** | ●(~0.07%) | | | **Valuation Comparison (based only on provided metrics):** | Comparison | Current | Reference | Assessment | |--------------------|--------------|-----------------|------------------------------------| | P/E (TTM) | 0.06x | Normal stocks often 10–20x | Looks insanely “cheap” but not reliable. | | P/S (TTM) | 0.21x | Many services 1–4x | Very low multiple for a services biz. | | vs Peers/History | [N/A] | [N/A] | No reference data provided. | **What the Current Valuation is Betting On:** - The market is *not* giving them much credit for their very bold RAK JV profit projections. - At this tiny size and ultra-low multiples, **the price suggests investors are skeptical** either about: - the **quality of earnings**; - the **realizability** of the real estate/digital asset plans; or - the **ability to raise funds and execute**. In other words, the stock screens as “dirt cheap,” but that’s often because the business is **very risky or misunderstood**, especially in micro-caps with exotic projects. --- ### 📰 Any Recent News? | Date (approx) | Event | Impact | |---------------|-------|--------| | Dec 12, 2025 | NewGen to exercise option to convert Ras Al Khaimah (RAK) JV into a joint development, with projected profit boost from US$67m to US$123m, plus planned fundraising and presales. | **Positive on narrative**, but **high-risk**: if it works, it could transform the company; if financing, demand, or execution fail, projections won’t materialize. | This RAK move is the center of the current “story”: big Gulf real estate + fundraising + presales, which is a very different risk profile from a pure IVF clinic operator. --- ## 📊 Layer 3: 3-Minute Complete Analysis ### I. Detailed Financial Data We only have current TTM snapshot metrics, not multi-year series, so trend analysis is limited. **Profitability Trends:** | Metric | This Year (TTM) | Last Year | Year Before | 3-Year Trend | |------------|------------------|-----------|-------------|--------------| | Gross Margin | 31.5% | [N/A] | [N/A] | [N/A] | | Net Margin | 12.4% | [N/A] | [N/A] | [N/A] | | ROE | 92.6% | [N/A] | [N/A] | [N/A] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |----------------|-----------|-----------|-------------|--------------| | Revenue Growth | [N/A] | [N/A] | [N/A] | [N/A] | | Profit Growth | [N/A] | [N/A] | [N/A] | [N/A] | | EPS Growth | [N/A] | [N/A] | [N/A] | [N/A] | Because we lack time-series data, you should assume **high uncertainty** around earnings stability. --- ### II. Earnings Track Record We don’t have quarterly EPS vs. expectations in the dataset. | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | [Most Recent] | [N/A] | [N/A] | [N/A] | **Earnings Trend Interpretation:** - With **no history of beats/misses** available and such a small market cap, this is likely **not widely covered by major analysts**. - In practice, this often means **limited institutional attention** and **higher sensitivity to news, rumors, and single projects**. --- ### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------------------|-------|------------| | Strong Buy / Buy | 0 | 0% | | Hold | 0 | 0% | | Sell | 0 | 0% | No analyst recommendation data → essentially **no mainstream coverage** in the dataset. **Target Price:** [Data unavailable] **vs Current Price:** [N/A] **Insider Activity:** Recent insider transactions: **[No data provided]** - Without insider buying/selling data, we **can’t infer** management’s conviction from their own money. - For micro-caps, **insider behavior can be very telling**, so this is a notable data gap. --- ### IV. Key Risk Alerts 1. **Business Model Drift & Complexity:** From fertility to digital assets and real estate JVs, the business scope is all over the place → This can dilute focus, make performance harder to understand, and increase the chance of **management overreach**. 2. **Execution & Financing Risk (RAK Project):** The Ras Al Khaimah joint development is ambitious and capital-intensive → If presales, fundraising, or construction timelines slip, the **projected US$123m profit uplift may never arrive**, and dilution or financial strain are real possibilities. 3. **Micro-cap / Liquidity & Governance Risk:** With a market cap under US$1m, daily trading volume may be tiny and spreads wide → You can see **sharp price swings**, difficulty entering/exiting size, and you’re heavily exposed to **key-person risk and governance quality**, which we cannot fully assess from the data here. --- ## 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** NewGenIvf is a very small Thailand-based company on Nasdaq that started in fertility but is now pitching a broader ecosystem involving digital assets and Gulf real estate development. > **Key strength:** It has minimal debt, a decent gross margin, and a highly “option-like” upside story if its Ras Al Khaimah project and other initiatives actually deliver anything close to the projected profits. > **Key risk:** The company is tiny, its financials and business mix are hard to interpret, and the bold profit projections rely on high-risk execution and financing, making this more suitable—if at all—for speculative capital that can tolerate the possibility of large losses or illiquidity. > **🔍 Want to Learn More?** > > • Curious if this “ecosystem” has any real moat or if it’s just buzzwords? → Try【Buffett Mode】to dissect competitive advantages and business quality. > • Worried about potential landmines in the JV contracts or related-party deals? → Try【Muddy Mode】for a focused risk and governance scan. > • Thinking of it as a high-risk/high-reward bet tied to the RAK project? → Try【Musk Mode】to map scenarios (success, delay, failure) and what each might imply for valuation.